Progress of pomalidomide for treatment of relapsed/refractory multiple myeloma / 肿瘤研究与临床

ABSTRACT

Multiple myeloma (MM), ranking the second most common malignancy in the blood system, is a heterogeneous disease characterized by clonal proliferation of plasma cells producing immunoglobulin. Due to the wide use of new drugs, including proteinase inhibitor (PI), immune modulators (IMiD) and monoclonal antibodies, great progress has been made in the treatment of MM, but almost all patients eventually develop drug resistance. Pomalidomide is the third generation of IMiD and a very well tolerated regimen for relapsed/refractory MM. This paper summarizes the combined therapy based on pomalidomide to provide the theoretical basis for a better clinical application of pomalidomide.